Chemotherapy Induced Peripheral Neuropathy

Multiple Myeloma

The algorithm (computer query) will identify all patients who received bortezomib-based chemotherapy for the multiple myeloma indication between 2008 and 2016. All the questionnaires used are validated in the scientific literature.

Bortezomib

CHU Clermont-Ferrand

Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders.

Evaluation of the Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders: Monocentric Observational and Cross-sectional Study.

Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 (QLQ-CIPN20 ; EORTC- European Organisation for Research and Treatment of Cancer).
The questionnaire is divided in 3 subscales: sensory, motor and vegetative. Severity scores summed from 0 to 100. A high score will correspond to the worst symptoms.
Sensory score CIPN20 ≤ 6 = grade 0 NCI-CTCAE
Sensory score CIPN20 > 6 and < 30 = grade 1 NCI-CTCAE
Sensory score CIPN20 ≥ 30 and < 80 = grade 2-3 NCI-CTCAE
Sensory score CIPN20 ≥ 80 = grade 4 NCI-CTCAE.

Pain score rated by a Visual Analog Scale (VAS, 0 (no pain) - 10 (worst possible pain)). Pain will be defined for a score of 4/10.

DN4 questionnaire interview (positive score> 3/7), if VAS pain> 4

Hospital Anxiety and Depression Scale (HADS, summed score from 0 to 21). Score ≤ 7 = no symptomatology, score between 8-10 = suspect symptomatology and score ≥ 11 = consistent symptomatology.

EVA and questions exploring possible hearing problems (professional or leisure activity exposing to noise, habit of having people repeat themselves, problems with telephone comprehension, need to increase television volume, difficulty following a conversation in the presence of noise).

Quality of Life Questionnaire - Chemotherapy 30 (QLQ-C30, EORTC-European Organisation for Research and Treatment of Cancer).
The questionnaire is divided in 3 subscales: Global health, functional and symptomatic.
Severity scores summed from 0 to 100. For the global health scale and the functional scale, a high score will correspond to a better quality of life. For the symptomatic scale, a high score will correspond to a lower quality of life.

University Hospital, Clermont-Ferrand

Bortezomib Regimen

Adult

bortezomib

Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple

Assessment of Sensory Disorders Associated With Peripheral Neuropathy Induced by Bortezomib: Prospective Comparative Study

Laboratoires Takeda

Marqibo® (Vincristine sulfate liposomal) will be administered intravenously over 60 minutes (±10 minutes) every 7 days (±3 days) (Days 1, 8, 15, 22) for four doses (1 cycle). Cycles may be repeated every 28 days for a maximum of 6 cycles; additional cycles may be offered with evidence of acceptable toxicity and clinical benefit.
The trial follows a rolling phase I design with 2 to 6 subjects per dose level and standard definitions of MTD and DLT. At the MTD, a total of 6 additional subjects with relapsed or refractory ALL will be evaluated.
Detailed pharmacokinetic studies will be performed during the first treatment cycle

Sarcoma

Neuroblastoma

Wilms Tumor

Leukemia

Lymphoma

Brain Tumors

Marqibo® intravenously (IV) over 60 minutes (+ 10 minutes) every 7 days (+ 3 days) for 4 consecutive weeks (day 1, 8, 15, 22) for a 28-day treatment cycle

Marqibo

National Institutes of Health Clinical Center, 9000 Rockville Pike

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer

Toxicity was graded according to the version 4.0 of the NCI Common Toxicity Criteria (CTCAE v4.0).

The MTD was defined as the dose level immediately below the dose level at which ≥2 subjects in a cohort of 2 to 6 subjects experienced a DLT.

DLT was graded according to the version 4.0 of the NCI Common Toxicity Criteria (CTCAE v4.0). Adverse events (AEs) that were considered disease-related (not suspected of relationship to Marqibo) were not considered dose-limiting toxicities. Only those AEs deemed suspected of a relationship to Marqibo were used in the definition of DLT.

PK samples were collected at cycle 1 before start of first infusion, 5 minutes post-infusion and at 1, 3, 6, 10, 24, 48, 72, 96, 120 and 144 hours (pre-dose #2 trough level). Area under the concentration time curve (AUC) to last measured time point after dose one was calculated via linear trapezoidal method and extrapolated to infinity (AUC0-∞) by adding the last plasma concentration after dose one divided by the rate constant, derived from the slope of the natural log-transformed concentrations and times on the terminal elimination phase of the concentration-time curve.

Acrotech Biopharma LLC

National Cancer Institute (NCI)

Phase 1 Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo® (Vincristine Sulphate Liposomes Injection) in Children and Adolescents with Refractory Cancer

catharanthus roseus/antimicótico

Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders.

Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

O mais completo banco de dados de ervas medicinais apoiado pela ciência